Every 8-K that Annovis Bio, Inc. (ANVS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANVS filings page.
Annovis Bio, Inc. reported significantly higher operating losses for the quarter and six months ended June 30, 2026 while advancing its lead Alzheimer’s program. The company fully enrolled its pivotal Phase 3 trial in early Alzheimer’s disease with 850 patients and is planning an open-label extension to allow continued buntanetap treatment after trial completion. Topline data are targeted for early 2027, and preparations for a potential regulatory submission have begun.
For the quarter, operating expenses rose to $14.4 million from $6.3 million a year earlier, driven by research and development of $12.0 million versus $5.2 million. Net loss widened to $14.8 million from $6.2 million, and to $32.4 million for the first half of 2026 from $11.8 million. The balance sheet showed cash and cash equivalents of $18.7 million and a large increase in warrant liability to $19.9 million, resulting in negative stockholders’ equity of $(4.3) million as of June 30, 2026.
Annovis Bio, Inc. reported that it has fully enrolled its pivotal Phase 3 trial (NCT06709014) of oral buntanetap in patients with early Alzheimer’s disease. The study enrolled 850 patients with pTau217-confirmed Alzheimer’s pathology across 83 clinical sites in the United States, exceeding the company’s original enrollment projections.
The randomized, placebo-controlled, double-blind dual trial evaluates daily 30mg buntanetap in early Alzheimer’s patients with MMSE scores of 20–28. Primary endpoints focus on changes in cognition using ADAS-Cog13 and function using ADCS-iADL. The design includes two pre-specified analyses: a 6‑month symptomatic readout and an 18‑month disease-modifying readout, each intended to support a separate NDA submission.
The last patient is expected to complete the 6‑month treatment period in January 2027, with top-line symptomatic data targeted for Q1 2027 and disease-modifying data in Q1 2028. Annovis has begun preparations for New Drug Application submissions to the FDA following each respective data readout.
Annovis Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where all five proposals received the required stockholder approval. Stockholders elected five directors for one-year terms and ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm.
Investors also approved an amendment to the 2019 Equity Incentive Plan, increasing the total shares available from 4,000,000 to 5,500,000 and raising the maximum annual award from 400,000 to 600,000 shares. Stockholders gave advisory approval to executive compensation and recommended holding future say‑on‑pay votes every two years, a frequency the board has adopted until the next required vote on this topic.
Annovis Bio, Inc. entered an underwriting agreement for an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants, targeting gross proceeds of about $15 million before expenses. Each share is sold together with nine-tenths of a warrant at a combined price of $1.90.
The warrants cover up to 7,105,500 shares, are immediately exercisable at $2.25 per share, and expire six years after issuance. Annovis plans to use the net proceeds primarily to continue clinical development of its lead drug candidate buntanetap for Alzheimer’s and Parkinson’s disease, and for working capital and general corporate purposes.
Annovis Bio reported first quarter 2026 results showing heavier spending as its late-stage programs advanced. Research and development expenses rose to $16.7M from $5.0M a year earlier, driving a net loss of $17.6M compared with $5.5M in the prior-year quarter, or $0.63 per share diluted versus $0.32.
Cash and cash equivalents were $14.2M as of March 31, 2026, down from $19.5M at year-end, while total liabilities increased to $13.1M and stockholders’ equity declined to $3.1M. The company highlighted progress for its oral therapy buntanetap, with its Phase 3 Alzheimer’s trial on track to finish patient randomization in summer 2026 and deliver first top-line data in early 2027, and a Parkinson’s disease open-label extension study now underway.
Annovis Bio, Inc. is raising approximately $10 million through an underwritten registered direct offering of 5,263,156 shares of common stock and accompanying warrants to buy 5,263,156 additional shares. Each share-and-warrant combination is priced at $1.90, and the warrants have an exercise price of $2.50 per share, becoming exercisable six months after issuance and expiring about five and a half years later.
The company expects the offering to close on or about April 10, 2026, subject to customary conditions, with Canaccord Genuity acting as underwriter and sole bookrunner. Annovis plans to use the net proceeds primarily to continue Phase 3 clinical development of its lead drug candidate buntanetap for Alzheimer’s disease, as well as for working capital and general corporate purposes.
Annovis Bio, Inc. reported that effective March 23, 2026, Chief Financial Officer Mark Guerin is no longer employed by the company. The company stated that his departure did not arise from any disagreement regarding operations, policies, or practices.
The board of directors is expected to appoint Chief Executive Officer Maria Maccecchini to serve as Acting Chief Financial Officer until a permanent replacement is identified, temporarily combining the CEO and CFO responsibilities.
Annovis Bio, Inc. reported full-year 2025 results while advancing its lead drug buntanetap into later-stage trials. The company initiated a pivotal Phase 3 study in early Alzheimer’s disease and started an open-label extension study in Parkinson’s disease, highlighting biomarker data that suggest a potential disease-modifying effect.
For the year ended December 31, 2025, research and development expenses were $25.2 million versus $20.0 million in 2024, while general and administrative expenses were $4.5 million versus $6.7 million. Total operating expenses reached $29.7 million, leading to a net loss of $28.9 million compared with $24.6 million a year earlier. Basic net loss per share was $1.40 versus $2.02.
Cash and cash equivalents were $19.5 million as of December 31, 2025, up from $10.6 million at year-end 2024. Total stockholders’ equity increased to $16.9 million from $9.3 million, reflecting capital raised to support the expanded clinical program.
Annovis Bio reported that an independent Data and Safety Monitoring Board completed a planned 6‑month safety review of its pivotal Phase 3 Alzheimer’s disease trial of buntanetap and recommended the study continue without changes. The DSMB found no safety concerns, and 6‑month safety data in Alzheimer’s patients were consistent with those previously observed in Parkinson’s patients.
The Phase 3 Alzheimer’s trial is recruiting across the United States and is about 40% complete. The first symptomatic efficacy results are expected in early 2027, followed by a disease‑modifying readout in early 2028. The company also noted that, given the aligned safety outcomes across Alzheimer’s and Parkinson’s studies, the FDA indicated it may consider accepting combined safety data in a future NDA submission.
Annovis Bio, Inc. filed a current report describing a planned investor communication. On January 28, 2026, the company will conduct a webinar to present information about its business or programs. The slide presentation for this webinar is being made available as Exhibit 99 and is incorporated by reference into the report.
The filing does not describe the webinar content in detail but makes clear that interested parties can review the full presentation materials through the attached exhibit.
Annovis Bio, Inc. filed a current report stating that it has released its latest earnings information. On November 12, 2025, the company issued a press release reporting financial results for the quarter and nine months ended September 30, 2025. The press release, which contains the detailed figures and discussion of the results, is attached to the report as Exhibit 99 and incorporated by reference.
Annovis Bio entered into a registered direct offering and director subscriptions to issue an aggregate of 1,670,732 common shares at $2.05 per share. The company expects gross proceeds of approximately $3.425 million, before expenses. Of the total, 597,561 shares are being sold to purchasers under a Securities Purchase Agreement, and 1,073,171 shares are being purchased by two board members via Stock Subscription Agreements.
The closing is expected on or about October 28, 2025. Annovis plans to use net proceeds to continue clinical development of Buntanetap in a Phase 3 study for Alzheimer’s disease, and for working capital and general corporate purposes. The company agreed to issuance restrictions: no new securities without purchaser consent until November 28, 2025, and no Variable Rate Transactions until October 14, 2026, subject to exceptions.
A placement agent will receive a 7.0% cash fee on gross proceeds excluding shares sold to directors and executive officers. The placement agent will also receive immediately exercisable warrants to purchase up to 83,537 shares, with a five-year term and a $2.5625 exercise price; these warrants and underlying shares are registered under the same prospectus supplement.
Annovis Bio (ANVS) announced a registered direct offering, agreeing to sell 3,150,000 shares of common stock at $1.50 per share and pre-funded warrants to purchase up to 850,000 shares at $1.4999 (with a $0.0001 exercise price). The company expects gross proceeds of approximately $6.0 million, before fees and expenses. The transaction is expected to close on or about October 14, 2025, after customary conditions.
The company plans to use net proceeds to continue clinical development of its lead compound Buntanetap in a Phase 3 Alzheimer’s study and for working capital and general corporate purposes. Annovis agreed for one year not to enter into Variable Rate Transactions, subject to exceptions, and obtained 45‑day lock-ups from directors and officers. The placement agent will receive a 7% cash fee, up to $50,000 for counsel plus $10,000 clearing expenses, and warrants to purchase 200,000 shares at $2.20, exercisable immediately for five years. The securities are offered under an effective Form S-3 and a prospectus supplement dated October 10, 2025.
Annovis Bio, Inc. appointed Mark Guerin, age 57, as its new Chief Financial Officer effective September 25, 2025. He previously served as CFO of Onconova Therapeutics, now Traws Pharma, Inc., from 2016 through February 2025, and holds a bachelor’s degree in accounting plus CPA, CMA, and CFM certifications.
His compensation package includes an annual base salary of $450,000, an annual target bonus of 40%, stock options to purchase 200,000 shares of Annovis Bio common stock, six months of severance pay, and eligibility to participate in the company’s standard employee benefit plans. The company stated there are no related-party transactions requiring disclosure between Annovis Bio and Mr. Guerin and issued a press release announcing his appointment.
Annovis Bio, Inc. reported that Andrew Walsh, its Vice President of Finance and Principal Financial Officer, resigned effective August 22, 2025. The company stated that his resignation did not result from any disagreement over operations, policies, or practices.
On August 15, 2025, the board unanimously appointed Chief Executive Officer Maria Maccecchini to also serve as Acting Chief Financial Officer. Annovis Bio indicated it is actively searching for a permanent Chief Financial Officer to fill the role.
Annovis Bio, Inc. furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. The filing indicates the press release is included as Exhibit 99.1 and also includes the Cover Page Interactive Data File as Exhibit 104. The registrant is identified as an emerging growth company and has elected not to use the extended transition period for new or revised accounting standards.
The 8-K text itself does not present the numerical results or additional operational details; those items are contained in the referenced press release furnished as an exhibit.
Annovis Bio, Inc. (NYSE: ANVS) filed a Form 8-K reporting the outcome of its 2025 virtual Annual Meeting held on 17 June 2025.
Quorum: 11,588,981 shares (59.47% of shares outstanding).
Proposal 1 – Election of Directors (one-year terms):
- Maria Maccecchini – 4,216,112 FOR / 173,438 WITHHELD / 7,199,431 broker non-votes
- Michael Hoffman – 4,182,806 FOR / 206,744 WITHHELD / 7,199,431 broker non-votes
- Claudine Bruck – 4,041,007 FOR / 348,543 WITHHELD / 7,199,431 broker non-votes
- Reid McCarthy – 4,202,391 FOR / 187,159 WITHHELD / 7,199,431 broker non-votes
- Mark White – 3,780,238 FOR / 609,312 WITHHELD / 7,199,431 broker non-votes
Proposal 2 – Ratification of Independent Auditor: Ernst & Young LLP ratified with 11,382,542 FOR, 187,959 AGAINST, 18,480 ABSTAIN.
All proposals passed; no additional matters were presented.
Annovis Bio, Inc. (NYSE: ANVS) filed an 8-K on June 19, 2025 to disclose that the New York Stock Exchange has accepted the company’s previously submitted listing-compliance plan. The plan was required after Annovis fell out of compliance with NYSE continued-listing standards; acceptance removes the immediate risk of delisting and starts a defined remediation timetable. The 8-K furnishes, but does not file, a press release (Exhibit 99.1) announcing the NYSE decision. No financial statements, earnings data or major transactions were included, and the disclosure is made solely under Item 7.01 (Regulation FD) with no impact on historical financial reporting.
Investors should note that, while acceptance is a constructive step, Annovis must still meet the milestones outlined in the compliance plan to regain full compliance. The filing contains no new operational or financial metrics.